Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1347 - Circulating tumor cells as an early predictive marker of disease progression in metastatic breast cancer patients

Date

10 Oct 2016

Session

Poster display

Presenters

Samy Algizawy

Citation

Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365

Authors

S.M. Algizawy1, H.H. Essa1, E. El-Gezawy2, N.N. Omar3, D.M. Sayed4

Author affiliations

  • 1 Clinical Oncology, Assiut University Hospitals, 71516 - Assiut/EG
  • 2 Clinical Pathology, Assiut University Hospitals, 7111 - Assiut/EG
  • 3 Radiology, Assiut University Hospitals, Assiut/EG
  • 4 Clinical Pathology, South Egypt Cancer Institute SECI Assiut University, Assiut/EG
More

Resources

Abstract 1347

Background

Circulating tumor cells (CTCs) are a prognostic marker in metastatic breast cancer, but their predictive value to monitor treatment efficacy still needs further investigation. The aim of this study was to test whether persistent elevation of circulating tumor cells (CTCs) at both baseline and before 2nd cycle of a new treatment can serve as an early predictive marker of disease progression in patients with metastatic breast cancer using the predefined 5 CTC/7.5 ml threshold.

Methods

Eighty-five patients with stage IV breast cancer who met the eligibility criteria were enrolled in the study. Before starting a new treatment, all patients underwent full imaging studies and blood sampling for CTC enumeration. Patients with 

Results

At baseline, 44 (51.8%) of the 85 eligible patients did not have increased CTC levels. Of the other 41 patients with ≥ 5 CTCs /7.5 ml blood, only 38 patients had CTCs evaluation at first follow-up before 2nd cycle (CTCFU) that showed 25 (65.8 %) patients had 

Conclusions

This study supports the significance of elevated CTCs before C2 in MBC patients starting a new line of chemotherapy as an early predictive marker of disease progression, thus, monitoring treatment benefit. It confirmed the independent prognostic significance of CTCs.

Clinical trial identification

not applicable, no trial protocol number

Legal entity responsible for the study

The Ethics Committee of the Faculty of Medicine, Assiut University

Funding

Assiut University Hospitals

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings